KalVista Pharmaceuticals, Inc. (KALV) Dividend History

Company News

• Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

  The FDA approved Ionis Pharmaceuticals' Dawnzera, the first RNA-targeted medicine for preventing hereditary angioedema (HAE) attacks in patients 12 and older, demonstrating significant attack rate reduction in clinical trials.

  Benzinga

  Featured Companies: BCRX IONS
• Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

  The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.

  GlobeNewswire Inc.

  Featured Companies: ATXS CAMP IONS NTLA
• Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?

  Here is how Amneal Pharmaceuticals (AMRX) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.

  Zacks Investment Research

  Featured Companies: AMRX
• KalVista's Sebetralstat: A Pill Worth Swallowing In HAE

  KalVista is positioned to disrupt the HAE treatment landscape with its oral therapy, sebetralsta. Read why I recommend a speculative Buy for KALV stock.

  Seeking Alpha
• Is BioCryst a Good Stock to Buy Now?

  This commercial-stage drugmaker trades for less than many of its clinical-stage peers.

  The Motley Fool

  Featured Companies: BCRX